India-based Dr. Reddy's Laboratories says that net income for the fourth quarter doubled to $75 million due to strong generic drug sales in the U.S., as reported in Pharma Times.
Sales climbed 23% to $451 million, mainly to a 68% leap in revenues from North America. Sales of a generic version of Sanofi's antihistamine Allegra D24 (extended-release fexofenadine/pseudoephedrine), launched after a New Jersey court lifted an injunction on the product at the beginning of the year, was one thing that increased Dr. Reddy’s profits.
The pharma also did well in Russia and other Commonwealth of Independent States, where revenues rose 26%. In Europe, sales fell 5% to 2.00 billion rupees, due principally to pricing pressures in Germany, while domestically, turnover was up 5% to 2.80 billion rupees.